ABT 436
Alternative Names: ABT-436Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Abbott Laboratories
- Developer Abbott Laboratories; AbbVie; National Institute on Alcohol Abuse and Alcoholism
- Class Antidepressants; Anxiolytics
- Mechanism of Action Vasopressin 1b receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alcoholism; Anxiety disorders; Major depressive disorder
Most Recent Events
- 01 Mar 2015 AbbVie completes a phase II trial in Alcoholism in USA (NCT01613014)
- 04 Oct 2013 AbbVie terminates phase II trial in Major depressive disorder in the US (NCT01741142)
- 03 Jun 2013 AbbVie suspends a phase II trial in Major depressive disorder in USA (NCT01741142)